Literature DB >> 2341303

On the peptide model of allorecognition: cytotoxic T lymphocytes recognize an alloantigen encoded by two HLA-linked genes.

D J Schendel1.   

Abstract

The peptide model of allorecognition hypothesizes that alloreactive cytotoxic T lymphocytes recognize peptides associated with major histocompatibility complex (MHC) molecules. This study characterizes an unusual alloantigen that is recognized by two human cytotoxic T-cell lines and may represent a complex formed by the association of a naturally selected peptide with an MHC molecule. Family studies demonstrate that both components of the alloantigen are products of MHC-linked genes. One component is a class I molecule most likely encoded by the HLA-B locus. The second component is encoded by an MHC-linked gene that shows a limited polymorphism; whether it represents the product of a second class I gene or of some other MHC gene remains to be determined. These data provide experimental evidence supporting the peptide model of allorecognition in human beings and indicate that some naturally selected peptides involved in allorecognition may be derived from MHC-encoded proteins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341303     DOI: 10.1016/0198-8859(90)90053-r

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  3 in total

1.  Allelic variants of the human putative peptide transporter involved in antigen processing.

Authors:  M Colonna; M Bresnahan; S Bahram; J L Strominger; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule.

Authors:  B P Chen; A Madrigal; P Parham
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

3.  A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules.

Authors:  F Kievits; P Ivanyi
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.